{"id":"W3043005157","doi":"10.1158/1538-7445.pedca19-ia16","title":"Abstract IA16: Accelerating innovation for children with cancer in the new regulatory environment","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Blinatumomab; Drug development; Marketing authorization; Pediatric cancer; Pediatric oncology; Waiver; Orphan drug; Cancer; Milestone; Disease; Oncology; Intensive care medicine; Internal medicine; Drug; Lymphoblastic Leukemia; Leukemia; Pharmacology; Bioinformatics","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03748738,0.0007290992,0.0004437873,0.001394029,0.002472416,0.01224075,0.002986092,0.01078772,0.05763219],"category_scores_gemma":[0.05429602,0.0003403526,0.001928438,0.001061773,0.003123736,0.007840673,0.008957973,0.012987,0.01682896],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00738288,"about_ca_system_score_gemma":0.04921982,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005571507,"about_ca_topic_score_gemma":0.005467322,"domain_scores_codex":[0.9696038,0.009930213,0.001214195,0.002177725,0.01224129,0.004832679],"domain_scores_gemma":[0.9332767,0.01103896,0.004965553,0.003858345,0.02082484,0.02603558],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001694434,0.0001984849,0.003532851,0.0004146577,0.00004763959,0.0003706778,0.0004012928,0.0006555997,0.00105188,0.1609623,0.7257296,0.1064656],"study_design_scores_gemma":[0.00007181614,0.0001336917,0.001390123,0.0004657267,0.00001225378,0.0001726181,0.0001879373,0.0002473878,0.0005709828,0.008236019,0.9884841,0.00002736215],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.008704121,0.01603919,0.0104193,0.6273127,0.02935296,0.0007834714,0.002450885,0.002138566,0.3027987],"genre_scores_gemma":[0.165579,0.02732467,0.03327248,0.4750724,0.02064944,0.001899184,0.00550574,0.001546155,0.269151],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.05763219,"threshold_uncertainty_score":0.1982545,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3324064938822954,"score_gpt":0.499763722472177,"score_spread":0.1673572285898816,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}